feb 14, 2018 - FDA held a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the new drug application for Hydexor (proposed tradename), a fixed-dose combination oral tablet, submitted by Charleston Laboratories, Inc., that contains hydrocodone, acetaminophen, and promethazine, for the short- term management of acute pain severe enough to require an opioid analgesic while preventing and reducing opioid-induced nausea
Added to timeline:
Date:
feb 14, 2018
Now
~ 8 years and 4 months ago